P3.18.87 EVEREST-2: Phase 1/2 Study of Logic-Gated Tmod CAR T A2B694 in Lung Cancer and Other Tumors Expressing MSLN With HLA-A*02 LOH
Year: 2025
Type: article
Source: Journal of Thoracic Oncology
Authors: S. Punekar, A. Chachoua, V. Velchetti, A.Z. Hazim, D.P. Karam, R.I. Marar, E.B. Garon, J.W. Goldman, J.P. Ward, J.C. Park, S.P. Patel, K.A. Gold, Y. Lou, A. Mardiros, Y. Mohseni, J. Welch, E.W.-C. Ng, W.Y. Go, D.G. Maloney, K. Kirtane, B. Creelan, J.W. Neal, A. Betof-Warner, M.V. Maus, J.R. Hecht, J.R. Molina
Institutions: NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Mayo Clinic, University of California, Los Angeles, Washington University in St. Louis, Massachusetts General Hospital, UC San Diego Health System, University of California San Diego, Moores Cancer Center, Mayo Clinic in Florida, Keymed Biosciences Inc. (China), Fred Hutch Cancer Center, Moffitt Cancer Center, Stanford Cancer Institute, Stanford University, UCLA Jonsson Comprehensive Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4415519099